静脉联合腹腔热灌注化疗对老年复发卵巢癌的临床效果

目的:对比分析静脉联合腹腔热灌注化疗与全身静脉化疗治疗老年复发卵巢癌的临床效果。方法:以2010年1月至2010年12月我院收治的80例老年复发卵巢癌患者为研究对象,行随机数字表法均分为观察组和对照组。观察组(n=40)行静脉联合腹腔热灌注化疗对照组(n=40)仅行全身静脉化疗。持续四个周期后统计疗效、不良反应,治疗前后CD3~+、CD4~+、CD4~+/CD8~+;持续随访,统计1年生存率、2年生存率、3年生存率、平均生存时间。结果觌察组总有效率(75.0%vs 52.5%)显著高于对照组;不良反应发生率(22.5%vs 80.0%)明显低于对照组;CD3~+、CD4~+、CD4~+/CD8~+均显著高于对照组;1年生存率(72.5%vs 55.0%)、2年生存率(27.5%vs 7.5%)均显著高于对照组;平均生存时间(16.8±2.1)月vs(13.8±1.8)月显著长于对照组。结论:静脉联合腹腔热灌注化疗治疗老年复发卵巢癌疗效显著,值得推广。

Clinical Effect of Intravenous Combined with Intraperitoneal Hyperthermic Perfusion Chemotherapy in the Treatment of Elderly Patients with Recurrent Ovarian Cancer

Objective:To compare the clinical effects of intravenous combined with intraperitoneal hyperthermic perfusion chemotherapy and intravenous chemotherapy in the treatment of elderly patients with recurrent ovarian cancer.Methods:80 cases of elderly patients with recurrent ovarian cancer accepted by our hospital from January 2010 to December 2010 were selected as the research object and divided into two groups. 40 patients in the observation group were treated by intravenous combined with intraperitoneal hyperthermic perfusion chemotherapy, while the other 40 patients in the control group were treated by systemic intravenous chemotherapy. The clinical effects, adverse reactions of patients were recorded. The CD3+, CD4+, CD4+/CD8+ indexes before and after treatment was detected, and the follow-up was also made to record the survival rate of1 year, 2 years and 3 years, and the average survival time.Results:The total effective rate of observation group (75.0 %vs 52.5 %) was significantly higher than that in control group; the incidence of adverse reaction in the observation group (22.5 %vs 80.0 %) was significantly lower than that of the control group; CD3+, CD4+, CD4+/CD8+ of the observation group were significantly higher than those in the control group; the one-year''s survival rate of the observation group (72.5 % vs 55 %), the 2 year survival rate of the observation group (27.5%vs 7.5%) were significantly higher than that of control group; the average survival time of the observation group (16.8± 2.1 vs 13.8± 1.8) m was significantly longer than that of the control group.Conclusion:Intravenous combined with intraperitoneal hyperthermic perfusion chemotherapy shows a significantly cura- tive effect in the treatment of senile recurrent ovarian cancer, which is worthy of promotion.